Skip main navigation
Close Drawer MenuOpen Drawer Menu

Direct Oral Anticoagulants Versus Warfarin Across the Spectrum of Kidney Function: Patient-Level Network Meta-Analyses From COMBINE AF

Originally published12 Apr 2023https://doi.org/10.1161/CIRCULATIONAHA.122.062752Circulation. 2023;147:1748–1757

    Abstract

    Background:

    There is uncertainty surrounding the use of direct oral anticoagulants (DOACs) in patients with kidney dysfunction.

    Methods:

    Using the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) database (data from RE-LY [Randomized Evaluation of Long-term Anticoagulation Therapy], ROCKET AF [Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation], ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation], and ENGAGE AF-TIMI 48 [Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in Myocardial Infarction 48]), we performed an individual patient-level network meta-analysis to evaluate the safety and efficacy of DOACs versus warfarin across continuous creatinine clearance (CrCl). A multivariable Cox model including treatment-by-CrCl interaction with random effects was fitted to estimate hazard ratios for paired treatment strategies (standard-dose DOAC, lower-dose DOAC, and warfarin). Outcomes included stroke and systemic embolism (S/SE), major bleeding, intracranial hemorrhage (ICH), and death.

    Results:

    Among 71 683 patients (mean age, 70.6±9.4 years; 37.3% female; median follow-up, 23.1 months), the mean CrCl was 75.5±30.5 mL/min. The incidence of S/SE, major bleeding, ICH, and death increased significantly with worsening kidney function. Across continuous CrCl values down to 25 mL/min, the hazard of major bleeding did not change for patients randomized to standard-dose DOACs compared with those randomized to warfarin (Pinteraction=0.61). Compared with warfarin, standard-dose DOAC use resulted in a significantly lower hazard of ICH at CrCl values <122 mL/min, with a trend for increased safety with DOAC as CrCl decreased (6.2% decrease in hazard ratio per 10-mL/min decrease in CrCl; Pinteraction=0.08). Compared with warfarin, standard-dose DOAC use resulted in a significantly lower hazard of S/SE with CrCl <87 mL/min, with a significant treatment-by-CrCl effect (4.8% decrease in hazard ratio per 10-mL/min decrease in CrCl; Pinteraction=0.01). The hazard of death was significantly lower with standard-dose DOACs for patients with CrCl <77 mL/min, with a trend toward increasing benefit with lower CrCl (2.1% decrease in hazard ratio per 10-mL/min decrease in CrCl; Pinteraction=0.08). Use of lower-dose rather than standard-dose DOACs was not associated with a significant difference in incident bleeding or ICH in patients with reduced kidney function but was associated with a higher incidence4 of death and S/SE.

    Conclusions:

    Standard-dose DOACs are safer and more effective than warfarin down to a CrCl of at least 25 mL/min. Lower-dose DOACs do not significantly lower the incidence of bleeding or ICH compared with standard-dose DOACs but are associated with a higher incidence of S/SE and death. These findings support the use of standard-dose DOACs over warfarin in patients with kidney dysfunction.

    Footnotes

    Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/CIRCULATIONAHA.122.062752.

    For Sources of Funding and Disclosures, see page 1756.

    Circulation is available at www.ahajournals.org/journal/circ

    Continuing medical education (CME) credit is available for this article. Go to http://cme.ahajournals.org to take the quiz.

    Correspondence to: Christopher B. Granger, MD, DCRI, Room 642, 300 W Morgan St, Durham, NC 27701. Email

    References

    • 1. Roberts PR, Green D. Arrhythmias in chronic kidney disease.Heart. 2011; 97:766–773. doi: 10.1136/hrt.2010.208587CrossrefMedlineGoogle Scholar
    • 2. Kumar S, Lim E, Covic A, Verhamme P, Gale CP, Camm AJ, Goldsmith D. Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week.J Am Coll Cardiol. 2019; 74:2204–2215. doi: 10.1016/j.jacc.2019.08.1031CrossrefMedlineGoogle Scholar
    • 3. Masson P, Webster AC, Hong M, Turner R, Lindley RI, Craig JC. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis.Nephrol Dial Transplant. 2015; 30:1162–1169. doi: 10.1093/ndt/gfv009CrossrefMedlineGoogle Scholar
    • 4. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, Ellinor PT, Ezekowitz MD, Field ME, Furie KL, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons.Circulation. 2019; 140:e125–e151. doi: 10.1161/CIR.0000000000000665LinkGoogle Scholar
    • 5. Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, Boriani G, Castella M, Dan GA, Dilaveris PE, et al; ESC Scientific Document Group. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.Eur Heart J. 2021; 42:373–498. doi: 10.1093/eurheartj/ehaa612CrossrefMedlineGoogle Scholar
    • 6. Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA, Patel MR, Wallentin L, Alexander JH, Cecilia Bahit M, et al; COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) Investigators. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex.Circulation. 2022; 145:242–255. doi: 10.1161/CIRCULATIONAHA.121.056355LinkGoogle Scholar
    • 7. Boehringer-Ingelheim. Pradaxa® (dabigatran etexilate) for U.S. healthcare professionals. Accessed April 10, 2023. https://pro.boehringer-ingelheim.com/us/products/pradaxa/Google Scholar
    • 8. Medscape. Savaysa (edoxaban) dosing, indications, interactions, adverse effects, and more. Accessed December 1, 2022. https://reference.medscape.com/drug/savaysa-edoxaban-999979Google Scholar
    • 9. XARELTO® (rivaroxaban): healthcare professional website. Accessed December 1, 2022. https://xareltohcp.com/dosing-all-indicationsGoogle Scholar
    • 10. Medscape. Eliquis (apixaban) dosing, indications, interactions, adverse effects, and more. Accessed December 1, 2022. https://reference.medscape.com/drug/eliquis-apixaban-999805Google Scholar
    • 11. Barra ME, Fanikos J, Connors JM, Sylvester KW, Piazza G, Goldhaber SZ. Evaluation of dose-reduced direct oral anticoagulant therapy.Am J Med. 2016; 129:1198–1204. doi: 10.1016/j.amjmed.2016.05.041CrossrefMedlineGoogle Scholar
    • 12. Campitelli MA, Bronskill SE, Huang A, Maclagan LC, Atzema CL, Hogan DB, Lapane KL, Harris DA, Maxwell CJ. Trends in anticoagulant use at nursing home admission and variation by frailty and chronic kidney disease among older adults with atrial fibrillation.Drugs Aging. 2021; 38:611–623. doi: 10.1007/s40266-021-00859-1CrossrefMedlineGoogle Scholar
    • 13. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation.N Engl J Med. 2009; 361:1139–1151. doi: 10.1056/NEJMoa0905561CrossrefMedlineGoogle Scholar
    • 14. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2013; 369:2093–2104. doi: 10.1056/NEJMoa1310907CrossrefMedlineGoogle Scholar
    • 15. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation.N Engl J Med. 2011; 365:981–992. doi: 10.1056/NEJMoa1107039CrossrefMedlineGoogle Scholar
    • 16. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.N Engl J Med. 2011; 365:883–891. doi: 10.1056/NEJMoa1009638CrossrefMedlineGoogle Scholar
    • 17. Hijazi Z, Hohnloser SH, Oldgren J, Andersson U, Connolly SJ, Eikelboom JW, Ezekowitz MD, Reilly PA, Siegbahn A, Yusuf S, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis.Circulation. 2014; 129:961–970. doi: 10.1161/CIRCULATIONAHA.113.003628LinkGoogle Scholar
    • 18. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, et al; ESC Scientific Document Group. The 2018 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.Eur Heart J. 2018; 39:1330–1393. doi: 10.1093/eurheartj/ehy136CrossrefMedlineGoogle Scholar
    • 19. Turpie AGG, Purdham D, Ciaccia A. Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment.Ther Adv Cardiovasc Dis. 2017; 11:243–256. doi: 10.1177/1753944717714921CrossrefMedlineGoogle Scholar
    • 20. Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, Keltai M, Lanas F, Lopes RD, Lopez-Sendon J, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial.Eur Heart J. 2012; 33:2821–2830. doi: 10.1093/eurheartj/ehs274CrossrefMedlineGoogle Scholar
    • 21. Bohula EA, Giugliano RP, Ruff CT, Kuder JF, Murphy SA, Antman EM, Braunwald E. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial.Circulation. 2016; 134:24–36. doi: 10.1161/CIRCULATIONAHA.116.022361LinkGoogle Scholar
    • 22. Fox KA, Piccini JP, Wojdyla D, Becker RC, Halperin JL, Nessel CC, Paolini JF, Hankey GJ, Mahaffey KW, Patel MR, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.Eur Heart J. 2011; 32:2387–2394. doi: 10.1093/eurheartj/ehr342CrossrefMedlineGoogle Scholar
    • 23. Nielsen PB, Lane DA, Rasmussen LH, Lip GY, Larsen TB. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis.Clin Res Cardiol. 2015; 104:418–429. doi: 10.1007/s00392-014-0797-9CrossrefMedlineGoogle Scholar
    • 24. Carnicelli AP, Hong H, Giugliano RP, Connolly SJ, Eikelboom J, Patel MR, Wallentin L, Morrow DA, Wojdyla D, Hua K, et al; COMBINE AF Investigators. Individual patient data from the pivotal randomized controlled trials of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation (COMBINE AF): design and rationale: from the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators.Am Heart J. 2021; 233:48–58. doi: 10.1016/j.ahj.2020.12.002CrossrefMedlineGoogle Scholar
    • 25. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.J Thromb Haemost. 2005; 3:692–694. doi: 10.1111/j.1538-7836.2005.01204.xCrossrefMedlineGoogle Scholar
    • 26. Schoenfeld D. Chi-squared goodness-of-fit tests for the proportional hazards regression model.Biometrika. 1980; 67:145–153. doi: 10.1093/biomet/67.1.145CrossrefGoogle Scholar
    • 27. Persson I, Khamis H. A comparison of graphical methods for assessing the proportional hazards assumptions in the Cox model.J Stat Applications. 2007; 2:1–32.Google Scholar
    • 28. Grambsch PM, Therneau TM. Modeling Survival Data: Extending the Cox Model. Springer; 2000.Google Scholar
    • 29. Alexander JH, Andersson U, Lopes RD, Hijazi Z, Hohnloser SH, Ezekowitz JA, Halvorsen S, Hanna M, Commerford P, Ruzyllo W, et al; Apixaban for Reduction of Stroke and Other Thromboembolic Complications in Atrial Fibrillation (ARISTOTLE) Investigators. Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial.JAMA Cardiol. 2016; 1:673–681. doi: 10.1001/jamacardio.2016.1829CrossrefMedlineGoogle Scholar
    Back to top

    Submit a Response to This Article

    Compose eLetter

    Contributors

    Statement of Competing Interests

    Cancel